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Shigella spp. are highly adapted human pathogens that cause bacillary dysentery
(shigellosis). Via the type III secretion system (T3SS), Shigella deliver a subset of virulence
proteins (effectors) that are responsible for pathogenesis, with functions including
pyroptosis, invasion of the epithelial cells, intracellular survival, and evasion of host
immune responses. Intriguingly, T3SS effector activity and strategies are not unique
to Shigella, but are shared by many other bacterial pathogens, including Salmonella,
Yersinia, and enteropathogenic Escherichia coli (EPEC). Therefore, studying Shigella
T3SS effectors will not only improve our understanding of bacterial infection systems,
but also provide a molecular basis for developing live bacterial vaccines and antibacterial
drugs. One ofShigella T3SS effectors, IpaH family proteins, which have E3 ubiquitin ligase
activity and are widely conserved among other bacterial pathogens, are very relevant
because they promote bacterial survival by triggering cell death and modulating the host
immune responses. Here, we describe selected examples of Shigella pathogenesis, with
particular emphasis on the roles of IpaH family effectors, which shed new light on bacterial
survival strategies and provide clues about how to overcome bacterial infections.
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INTRODUCTION
The interplay between enteric pathogens and the gastrointestinal (GI) tract is a critical determinant
of the fate of bacterial infection and disease progression. Shigella spp. are highly adapted human
pathogens that cause shigellosis, a disease that provokes severe bloody and mucous diarrhea, which
still remains a major public health concern in developing countries. No safe and effective Shigella
vaccine currently exists, and antibiotic-resistant bacteria have recently been observed, increasing
the threat of outbreaks due to lack of effective treatments (Barry et al., 2013). Therefore, there is an
urgent need to understand the interplay between bacterial infection and host cellular and immune
responses in order to develop safe and effective Shigella vaccines or novel treatment.
After ingestion via the fecal–oral route, Shigella preferentially invade the intestinal epithelium
viaM cells overlying the follicle-associated epithelium. Once Shigella are endocytosed byM cells,
they enter resident macrophages and induce inflammatory cell death (Wassef et al., 1989; Perdomo
et al., 1994). After being released from dying macrophages, the bacteria invade surrounding
epithelial cells, escape from the vacuole, andmultiply within the cytoplasm (Zychlinsky et al., 1992).
Subsequently, Shigellamove by inducing actin polymerization at one pole of the bacterium, thereby
spreading to neighboring cells (Suzuki et al., 1998, 2000; Egile et al., 1999). Thus, shigellosis is
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the consequence of multiple pathogenic events, including
macrophage cell death, invasion of and multiplication
within epithelial cells, cell-cell spread, and severe intestinal
inflammation.
The infection strategies of Shigella depend on the delivery
of bacterial virulence proteins, called “effectors,” into host cells
via the type III secretion system (T3SS) (Carayol and Tran
Van Nhieu, 2013; Ashida et al., 2015). The effectors, which
are delivered into both myeloid cells (macrophages, dendritic
cells, T, and B cells) and nonmyeloid cells (epithelial cells),
mimic or subvert host cellular functions, allowing Shigella to
colonize the intestinal epithelium. The diverse roles of effectors
include bacterial invasion into cells, intracellular survival and
multiplication, maintenance of an infectious foothold, and
modulation of the host immune response. Recent studies showed
that many T3SS effectors have novel and specific enzymatic
activities distinct from those of mammalian enzymes, e.g.,
phosphothreonine lyase, deamidase, and E3 ubiquitin ligase
(Li et al., 2007; Rohde et al., 2007; Sanada et al., 2012).
Moreover, T3SS effector activity and function is not specific
to Shigella but is shared by other enteric pathogens, including
Salmonella, Yersinia, and EPEC. Therefore, the study of effector
functions will improve our understanding of bacterial infection
mechanisms and facilitate development of novel vaccines or
drugs to overcome bacterial infection. Shigella is a good model
for such studies because it has many effectors, some of which
are common to other pathogens, and many of its strategies for
infection are widely conserved among other enteric bacterial
pathogens. In this review, we will highlight the role of one class
of Shigella T3SS effector, the IpaH family.
IpaH FAMILY EFFECTORS
Shigella possesses 12 ipaH genes, which reside on both the
large plasmid and the chromosome. The encoded IpaH proteins
are injected into host cells via the T3SS (Ashida et al., 2007).
IpaH family proteins contain N-terminal leucine-rich repeats
(LRRs) and have E3 ubiquitin ligase activity in their conserved
C-terminal regions (Rohde et al., 2007; Ashida et al., 2014a).
Ubiquitination is an important post-translational modification
that regulates several cellular functions, including cell signaling,
protein degradation, transcription, and endocytosis (Pickart,
2001). Ubiquitination is accomplished via a series of reactions
catalyzed by a multienzymatic cascade: E1 (ubiquitin-activating
enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin
ligase). The ubiquitination cascade starts with ATP-dependent
activation of ubiquitin via formation of a thioester linkage
between the carboxyl-terminal Gly of ubiquitin and a Cys
of E1. Activated ubiquitin is transferred to the active-site
Cys of E2, and finally E3 ligase mediates the transfer of
ubiquitin from the E2 to specific substrate proteins (mainly
via substrate Lys residues). E3 ligases can be categorized into
two groups based on their structures and functions: HECT
(Homologous to the E6-AP Carboxyl Terminus)-type and
RING (Really Interesting NewGene)/U-box-type. HECT-type E3
ligases catalyze ubiquitin transfer by accepting ubiquitin from E2
via formation of a thioester bond with their catalytic cysteine
residue, and then transfer ubiquitin to their target substrates.
On the other hand, RING/U-box-type E3 ligases catalyze direct
ubiquitin transfer by acting as scaffold molecules to bind and
recruit the E2-ubiquitin complex, and then directly transfer
ubiquitin from E2 to E3-bound substrates. Recent reports
showed that some bacterial pathogens deliver several types of
T3SS effectors with E3 ligase activity (Ashida et al., 2014a).
Because the ubiquitination pathway is absent in bacteria, bacteria
might deliver E3 ligase effectors and hijack the mammalian
ubiquitination pathway in order to counteract host responses.
IpaH family proteins are widely conserved among animal and
plant pathogens, including Shigella (IpaH), Salmonella (SspH1,
SspH2, and SlrP), Edwardsiella, Bradyrhizobium, Rhizobium,
and some Pseudomonas species, illustrating the importance of
these effectors in bacterial infection. Although IpaH family
proteins have E3 ubiquitin ligase activity and their C-terminal
domains contain a single conserved Cys that form a Cys-
ubiquitin intermediate similar to that of HECT-type ligases,
the catalytic domains of IpaH family members differ at the
sequence and structural levels from eukaryotic E3 ubiquitin
ligases. Consequently, IpaH family proteins are now considered
to constitute a new class of E3 ubiquitin ligases, NEL (Novel
E3 ligase), distinct from typical RING-, and HECT-types of E3
ubiquitin ligases (Singer et al., 2008; Zhu et al., 2008; Quezada
et al., 2009). Intriguingly, IpaH family proteins exhibit auto-
inhibition to prevent ubiquitination of unintended proteins.
Specifically, the LRR domain sequesters and masks the catalytic
Cys residue in the C-terminal region prior to substrate binding.
Once the LRR binds to substrate proteins, a conformational
change occurs, releasing the auto-inhibition of IpaH E3 ligase
activity (Quezada et al., 2009; Chou et al., 2012; Keszei et al.,
2014).
Although IpaH family proteins are highly similar to one
another, the sequences of their LRR regions, regarded as
substrate recognition sites, and subcellular localizations (e.g.,
nucleus, cytoplasm, or plasma membrane) are different. These
observations imply that each IpaH family protein has a specific
host target protein due to its unique subcellular localization
and substrate recognition domain, and thus makes a distinct
contribution to promotion of bacterial pathogenesis. Consistent
with this, recent studies have revealed the role of IpaH family
members in disabling distinct target proteins in host cells.
SHIGELLA IpaH EFFECTORS TARGET
NF-κB SIGNALING
The host innate immune system can detect markers of Shigella
infection as pathogen-associated molecular patterns (PAMPs)
and danger-associated molecular patterns (DAMPs), leading
to severe inflammatory colitis aimed at preventing and
clearing bacterial infection. However, many enteric bacterial
pathogens, including Shigella, are able to optimize the host
inflammatory responses to allow pathogen survival in such
inflamed environments by delivering a subset of T3SS effector
proteins (Rahman and McFadden, 2011; Ashida et al., 2015).
Because the nuclear factor κB (NF-κB) plays a pivotal role in
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the bacteria-induced inflammatory response, Shigella deliver
effectors that target and inhibit NF-κB signaling to modulate
the host inflammatory response (Ashida et al., 2015; Rahman
and McFadden, 2011). Recognition of PAMPs or DAMPs
by various sensors, including Toll-like receptors (TLRs) and
Nod-like receptors (NLRs), and subsequent signal transduction
through Myd88, TRAF, RIP, TAK1, and TAB2/3 trigger the
activation of IKK kinase complex. Once the IKK complex is
activated, it phosphorylates IκB (inhibitor of NF-κB), leading
to its ubiquitination and proteasome degradation. NF-κB then
translocates to the nucleus and activates the transcription
of proinflammatory cytokines (Hayden and Ghosh, 2012).
Because ubiquitination is an essential aspect of this regulatory
mechanism, Shigella deliver three IpaH effectors (IpaH9.8,
IpaH0722, and IpaH4.5) that subvert NF-κB activation by
manipulating the host ubiquitin system (Figure 1). After Shigella
invasion of epithelial cells, the host sensor Nod1 recognizes
peptidoglycans released from Shigella as PAMPs, triggering
NF-κB activation. IpaH9.8 preferentially prevents Nod1-
dependent NF-κB activation. Specifically, IpaH9.8 interacts
with NEMO/IKKγ, which is critical for downstream activation
of NF-κB, and targets NEMO (lysines 309 and 321 residues)
for ubiquitination. IpaH9.8 also interacts with ABIN-1, a
ubiquitin-binding adaptor protein and bridge IpaH9.8-NEMO,
to further promote polyubiquitination of NEMO. Ubiquitination
of NEMO by IpaH9.8 leads to proteasomal degradation, thereby
reducing NF-κB activation (Ashida et al., 2010). Consistent
with this model, the level of NEMO protein and Shigella-
induced NF-κB activation were decreased by IpaH9.8 E3 ligase
activity in NEMO-WT cells, but not in cells stably expressing
NEMO-K309R/K321R, a mutant lacking the IpaH9.8-mediated
ubiquitination site. The reduction in NF-κB activation due to
the activity of this E3 ligase effector during Shigella infection
results in downregulation of host inflammatory responses,
such as cytokine production and neutrophil recruitment, and
contributes to bacterial colonization in mouse models of lung
infection (Ashida et al., 2010). In addition to NEMO, IpaH9.8
also binds to the host splicing factor U2AF35 and inhibits the
U2AF35-dependent mRNA splicing reaction (Okuda et al.,
2005). Because IpaH9.8 ubiquitinates U2AF35 in vitro, it has
been proposed that IpaH9.8 diminishes the amount of U2AF35
and downregulates U2AF35-dependent pro-inflammatory gene
expression (Seyedarabi et al., 2010).
Another IpaH family protein, IpaH0722 localizes to host
cell plasma membrane via the modulation of S-palmitoylation
at N-terminal Cys14 and Cys18 residues. IpaH0722 E3
ligase preferentially inhibits phorbol myristate acetate (PMA)-
mediated NF-κB activation in NF-κB-luciferase reporter assays.
Since PMA mimics the role of diacylglycerol (DAG) in the
activation of the protein kinase C (PKC)-NF-κB pathway,
FIGURE 1 | Shigella IpaH effectors target host substrates for ubiquitination. (left: Macrophage) IpaH7.8 interacts with and ubiquitinates GLMN, leading to its
proteasome-dependent degradation. Degradation of GLMN abolishes its ability to inhibit inflammasomes, resulting in NLRP3/NLRC4 inflammasome activation and
pyroptosis. (right: Epithelial cell) IpaH0722, IpaH9.8, and IpaH4.5 target and ubiquitinate TRAF2, NEMO, and p65, respectively, which undergo proteasome
degradation, resulting in inhibition of NF-κB.
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IpaH0722 also inhibits PKC-mediated NF-κB activation (Ashida
et al., 2013). Intriguingly, DAG is recognized as the danger signals
that are generated by vacuolar membrane ruptures in Shigella
infection. When Shigella invades epithelial cells, the bacteria
are surrounded by a vacuolar membrane, but they rapidly
disrupt this membrane and disseminate into the cytoplasm. At
this step, Shigella-mediated vacuolar membrane ruptures are
recognized as DAMPs, triggering NF-κB activation through the
recruitment and activation of PKC. To counteract PKC–NF-
κB activation, Shigella delivers IpaH0722. IpaH0722 interacts
with TRAF2, a molecule downstream of PKC, and targets it for
ubiquitination. TRAF2 ubiquitinated by IpaH0722 is degraded
by the proteasome, thereby inhibiting PKC-mediated NF-κB
activation (Ashida et al., 2013). In addition to IpaH9.8 and
IpaH0722, Shigella also prevent NF-κB activation by delivering
IpaH4.5, which targets the p65 subunit of the NF-κB complex
targets it for ubiquitination in vitro (Wang et al., 2013).
In addition to the IpaH family, other Shigella effectors, such
as OspG, OspI, and OspZ, also manipulate the ubiquitination
system to inhibit NF-κB activation. OspG, which is homologous
to EPEC NleH, is a serine/threonine kinase that binds to
ubiquitin and ubiquitinated E2s to prevent phospho-IκBα
ubiquitination, which is required for NF-κB activation (Kim
et al., 2005; Zhou et al., 2013; Grishin et al., 2014; Pruneda
et al., 2014). Another Shigella effector, OspI, has deamidase
activity, which is shared by other effectors such as Cif from
EPEC and CHBP from Burkholderia pseudomallei. OspI targets
Ubc13, an E2 protein required for TRAF6 E3 ligase, and
converts Gln-100 of Ubc13 to Glu-100, thereby inactivating its E2
activity. Inactivation of Ubc13 by OspI blocks TRAF6-dependent
NF-κB signaling, thereby downregulating host inflammation
(Sanada et al., 2012). OspZ from S. flexneri 6 and S. boydii
blocks the nuclear translocation of NF-κB subunit p65, thereby
inhibiting NF-κB activation (Newton et al., 2010). Although it
remains unknown whether OspZ shares the same enzymatic
activity, EPEC T3SS effector NleE has methyltransferase activity
that specifically modifies zinc-finger cysteines of TAB2 and
TAB3, ubiquitin-chain binding proteins involved in the NF-
κB activation. Following cysteine methylation by NleE, TAB2,
and TAB3 lose their zinc ions and ubiquitin-chain binding
activities, making them unable to activate NF-κB (Zhang et al.,
2011).
Furthermore, Shigella hijack epigenetic modification to
modulate host innate immune responses. Shigella T3SS
effector OspF, which is homologous to Salmonella SpvC and
Pseudomonas syringae HopAl1, has a unique phosphothreonine
lyase activity (Arbibe et al., 2007; Kramer et al., 2007; Li et al.,
2007). OspF irreversibly dephosphorylates and inactivates
MAPKs. This inactivation of MAPK further inhibits downstream
phosphorylation of histone H3 at Ser10 at the promoters
of a subset of innate immune genes, and promotes chromatin
condensation, resulting in inhibition of transcriptional activation
by masking NF-κB binding sites (Arbibe et al., 2007). Recent
study further showed a novel function of OspF, which alters the
activity of the chromatin reader Heterochromatin Protein 1γ
(HP1γ) and reprograms host gene expression during Shigella
infection via its phosphothreonine lyase activity (Harouz et al.,
2014).
SHIGELLA IpaH EFFECTOR TARGETS
INFLAMMASOMES
In addition to NF-κB signaling, Shigella use IpaH proteins to
target inflammasome activation. As mentioned above, Shigella
invade resident macrophages, disrupt the phagosome vacuole,
disseminate into and multiply within the cytosol, and induce
a form of inflammatory cell death called pyroptosis, which is
accompanied by NLRP3 or NLRC4 inflammasome activation
and leads to IL-1β and IL-18 secretion (Suzuki et al., 2007;
Willingham et al., 2007; Ashida et al., 2011, 2014b; Davis et al.,
2011; Suzuki et al., 2014a). Pyroptosis is a specialized form of
cell death that is regulated by activated inflammatory caspases
(caspase-1 or caspase-11). Caspase-1 is activated by canonical
inflammasome (multiprotein complexes, such as NLRP3 or
NLRC4 and ASC) via recognition of T3SS components, whereas
caspase-11 directly binds to cytosolic LPS and forms non-
canonical inflammasomes; both complexes trigger the release
of proinflammatory cytokines (IL-1β and IL-18) and pyroptosis
(Kayagaki et al., 2011, 2013; Shi et al., 2014). Recent studies show
that activated caspase-1 and caspase-11 cleave GSDMD, and
the cleaved N-terminal domain of GSDMD induces pyroptosis
accompanied by cell lysis and release of cell contents (Kayagaki
et al., 2015; Shi et al., 2015).
Although pyroptosis seems like a host defense system aimed
at clearing bacterial infection, Shigella deliver IpaH7.8 to induce
inflammasome activation and pyroptosis via its E3 ligase activity
in order to escape from macrophages; otherwise, the bacteria
will be killed (Figure 1) (Suzuki et al., 2014b). In a mouse
model of lung infection, mice infected with the Shigella WT
or 1ipaH7.8/WT (IpaH7.8 WT complemented) strain exhibited
severe macrophage cell death and IL-1β secretion, whereas
those infected with the 1ipaH7.8 or 1ipaH7.8/CA (E3 ligase-
deficient mutant) strain did not. Notably, colonizing bacterial
number was significantly higher in mice infected with the
Shigella WT or 1ipaH7.8/WT strain than in mice infected with
1ipaH7.8 or 1ipaH7.8/CA mutants, illustrating the importance
of IpaH7.8-mediated cell death in Shigella infection. IpaH7.8
interacts with GLMN, which acts either directly or indirectly
as a negative regulator of the NLRP3/NLRC4 inflammasome,
and targets it for ubiquitination. GLMN ubiquitinated by
IpaH7.8 is subsequently degraded by the proteasome. GLMN
degradation abolishes its inhibitory activity and thus triggers
NLRP3/NLRC4 inflammasome activation and pyroptosis. To
further support this idea, Shigella-induced cytotoxicity and IL-1β
secretion levels were remarkably higher in macrophages derived
from GLMN+/− mice than in those from GLMN+/+ mice.
Furthermore, the number of internalized bacterial number was
also higher in the lungs of GLMN+/− mice (Suzuki et al.,
2014b). Therefore, induction of pyroptosis by IpaH7.8 is more
beneficial to Shigella than the host: specifically, it results in
further invasion of surrounding epithelial cells and spread to
neighboring cells, thereby promoting bacterial survival.
CONCLUSION
The lack of a licensed vaccine and the emergence of
antibiotic-resistant Shigella highlight the difficulty of controlling
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this pathogen and the need for new antimicrobial strategies.
Studying the course of Shigella infection, especially the
interaction between bacterial effectors and host cells, might
provide a means to resolve this problem. In this report, we
highlighted Shigella infection strategies mediated by IpaH family
effectors, including NF-κB inhibition and macrophage killing. As
mentioned above, IpaH family effectors are novel E3 ubiquitin
ligases that are widely conserved among Gram-negative bacterial
pathogens. The conservation of IpaH effectors among Shigella
and bacterial pathogens, and their critical roles in pathogenesis,
make them good targets for antibacterial drug or vaccine
candidates. Recent studies show that each IpaH protein interacts
with a specific host target protein via its LRR region, and then
modulates the ubiquitination of that target. In addition to the
Shigella IpaH family effectors, SspH1, SspH2, and SlrP from
Salmonella target and ubiquitinate PKN1, SGT1, and Nod1,
and thioredoxin, respectively (Haraga and Miller, 2006; Bernal-
Bayard and Ramos-Morales, 2009; Bhavsar et al., 2013; Keszei
et al., 2014). Although, the LRR regions of IpaH family effectors
are slightly different, each protein contains a catalytic Cys residue
that is required for transferring ubiquitin to substrate proteins.
Therefore, an inhibitor that could block or mask the catalytic Cys
residue of IpaH, or a conserved IpaH C-terminal-based vaccine,
would provide broad coverage across against many bacterial
pathogens. Therefore, the study of IpaH family effectors may lead
to the development of a single drug that is effective against many
infectious bacterial diseases.
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